文献速递膀胱癌与上尿路尿路上皮癌

Disitamab vedotin联合吉西他滨新辅助治疗肌层浸润性膀胱癌的疗效与安全性:开放标签、多中心、单臂2期试验

Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.
PubMed 文献 · Eur Urol · 2025-11-04

该研究纳入26例HER2 2+/3+的cT2-4aNxM0肌层浸润性膀胱癌患者,接受DV联合吉西他滨新辅助治疗,14天为一周期,13例接受3周期,13例接受4周期,其中22例后续行根治性膀胱切除术。术后病理pCR率在RC患者中为59%(13/22),意向性分析中总体pCR率为50%(13/26)。中位随访16.9个月时25例无事件,治疗相关不良事件主要为转氨酶升高、食欲下降、脱发和感觉神经病变。

要点

  • DV联合吉西他滨新辅助治疗在HER2 2+/3+ MIBC中显示较高pCR率,RC患者中为59%。
  • 4周期组的pCR率高于3周期组(RC患者中75% vs 40%,ITT中69% vs 31%)。
  • 常见治疗相关不良事件为AST升高(35%)、ALT升高(38%)、食欲下降(23%)、脱发(23%)和感觉神经病变(23%)。

核心结论

  • DV联合吉西他滨新辅助治疗在HER2 2+/3+的MIBC患者中显示出有前景的pCR率和可管理的安全性。

研究设计与样本

  • 开放标签、多中心、单臂2期试验,初始纳入26例cT2-4a Nx M0且HER2免疫组化评分2+/3+的MIBC患者。
  • 新辅助方案为DV 2 mg/kg静脉输注(第1天)联合吉西他滨1000 mg/m2静脉输注(第2天),14天为一周期。
  • 13例接受3周期,另13例接受4周期(非随机分配),随后22例接受根治性膀胱切除术。

主要发现

  • RC患者术后病理pCR率为59%(13/22),其中3周期组为40%(4/10),4周期组为75%(9/12)。
  • ITT分析总体pCR率为50%(13/26),3周期组为31%(4/13),4周期组为69%(9/13)。
  • 中位随访16.9个月时,25例患者保持无事件。

关键数值与推荐

  • 治疗相关不良事件主要包括AST升高(35%)、ALT升高(38%)、食欲下降(23%)、脱发(23%)和感觉神经病变(23%)。

临床怎么用

  • 对于不适合顺铂新辅助化疗的HER2 2+/3+ MIBC患者,DV联合吉西他滨可作为潜在的新辅助治疗选择。
  • 4周期方案可能较3周期方案提高pCR率,但需进一步验证。

局限性

  • 该方案长期疗效仍需验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are barriers to the clinical use of cisplatin-based neoadjuvant regimens in muscle-invasive bladder cancer (MIBC), especially for patients with renal dysfunction, hearing loss, heart diseases, or other severe comorbidities. Favorable efficacy and safety of disitamab vedotin (DV), an antibody-drug conjugate targeting HER2, have recently been demonstrated in urothelial carcinoma. We explored neoadjuvant gemcitabine combined with RC48 in the MIBC setting. Initially, 26 patients with clinical stage T2-4a Nx M0 MIBC and a HER2 immunohistochemical expression score of 2+/3+ were enrolled. The neoadjuvant regime comprised DV (2 mg/kg intravenous infusion, day 1) and gemcitabine (1000 mg/m2 intravenous infusion, day 2) in a 14-d cycle. Thirteen patients received three cycles, and the other 13 patients received four cycles, in a nonrandomized manner. Subsequently, 22 patients underwent radical cystectomy (RC). Postoperative pathology revealed a pathological complete response (pCR) rate of 59% (13/22) among RC patients, 40% (4/10) of whom had received three cycles and 75% (9/12), four cycles. Intention-to-treat analysis revealed pCR rates of 50% (13/26) overall, 31% (4/13) for the three-cycle group, and 69% (9/13) for the four-cycle group. At median follow-up of 16.9 mo, 25 patients remained event-free. Treatment-related adverse events primarily included aspartate aminotransferase elevation (35%), alanine aminotransferase elevation (38%), a decrease in appetite (23%), alopecia (23%), and sensory neuropathy (23%). Validation of the long-term efficacy of this regimen is required.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Huang H, Ma W, Zeng X, et al. Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial. Eur Urol. 2025. PMID: 41193372. doi:10.1016/j.eururo.2025.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。